Salarius Pharmaceuticals, Inc. (SLRX) |
|
2.42 -0.14 (-5.47%)
|
01-27 16:00 |
|
Open: |
2.61 |
Pre. Close: |
2.56 |
|
High:
|
2.76 |
Low:
|
2.35 |
|
Volume:
|
285,640 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:00 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 3.68 One year: 5.18 |
| Support: |
Support1: 1.07 Support2: 0.89 |
| Resistance: |
Resistance1: 3.15 Resistance2: 4.44 |
| Pivot: |
2.53  |
| Moving Average: |
MA(5): 2.59 MA(20): 2.29
MA(100): 2.97 MA(250): 5.28 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 29.2 %D(3): 34.9 |
| RSI: |
RSI(14): 52.7 |
| 52-week: |
High: 13.44 Low: 0.17 |
| Average Vol(K): |
3-Month: 168 (K) 10-Days: 745 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLRX ] has closed above bottom band by 42.1%. Bollinger Bands are 11% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.77 - 2.78 |
2.78 - 2.8 |
|
Low:
|
2.31 - 2.33 |
2.33 - 2.34 |
|
Close:
|
2.39 - 2.42 |
2.42 - 2.44 |
|
Company Description |
|
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. |
Headline News |
Fri, 27 Jan 2023
Will Salarius Pharmaceuticals Inc (SLRX) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Fri, 20 Jan 2023
Healthcare Stocks Moving Friday: COSM, EAR, HOWL, INM, SLRX, RNXT, NRSN, EVLO - InvestorsObserver
Fri, 20 Jan 2023
Thinking about buying stock in Salarius Pharmaceuticals ... - PR Newswire
Fri, 20 Jan 2023
Premarket Mover: Salarius Pharmaceuticals Inc (SLRX) Up 10.89% - InvestorsObserver
Thu, 19 Jan 2023
U.S. stocks lower at close of trade; Dow Jones Industrial Average ... - Investing.com
Thu, 19 Jan 2023
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
6.1 (%) |
|
% Held by Institutions
|
16.3 (%) |
|
Shares Short
|
37 (K) |
|
Shares Short P.Month
|
22 (K) |
Stock Financials |
|
EPS
|
-0.38 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.38 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-40.4 |
|
Return on Equity (ttm)
|
-99.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-2.95 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-9.05 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-6.42 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.32 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.36 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-07-21 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
